

16TH MEETING OF THE EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2021 VIRTUAL

SEPTEMBER 25 - 26, 2021

PROGRAMME

See you online!

*Be part
of the EANO
Virtual Experience!*



www.eano.eu

**EDUCATIONAL DAY
OCTOBER 23, 2021**



TABLE OF CONTENTS

Welcome Address.....	3
Board, Committees and Organisation	4
EANO Executive Board.....	4
EANO General Board	4
EANO Scientific Committee	4
EANO Educational Committee.....	4
EANO Office	5
EANO 2021 Conference Organisation	5
Accreditation.....	6
CME CREDITS EANO Meeting 2021	6
CME CREDITS EANO Educational Day 2021	6
EACCME® credits.....	6
CME CERTIFICATE/CONFIRMATION OF ATTENDANCE	6
Future Meetings.....	6
Scientific Programme & Information	7
EANO Meeting - Programme at a Glance	8
EANO Meeting – Saturday, September 25, 2021.....	10
EANO Meeting – Sunday, September 26, 2021.....	13
EANO Meeting – On-demand.....	18
E-Poster viewing with authors.....	20
EANO Educational Day – Programme at a Glance.....	21
EANO Educational Day – Saturday, October 23, 2021	22
EANO Educational Day – On-demand.....	24
Virtual Conference Format	25
Live Sessions	25
On-demand Sessions	25
E-Poster	25
Corporate Symposia.....	26
Corporate Symposium 1 Eisai.....	27
Brain tumour related epilepsy: what is the evidence for targeting the AMPA glutamate receptor?.....	27
Corporate Symposium 2 AstraZeneca.....	28
Evolving Landscape in the Treatment of Plexiform Neurofibromas Associated with NF1	28
Sponsors	30

WELCOME ADDRESS

Dear friends and colleagues,

As the European Association of Neuro-Oncology's (EANO) top priority is the safety and health of members, meeting participants, speakers, sponsors, exhibitors and suppliers the EANO has decided that the EANO 2021 Meeting and Educational Day will be held virtually due to the COVID-19 pandemic. The EANO Congress in Rotterdam, NL has been rescheduled to September 21-24, 2023 at the same conference venue.

Knowing how important our annual meeting is to the field of neuro-oncology in Europe and the patients we serve, it is a great pleasure to invite you to join us online for the 16th annual EANO meeting from September 25-26, 2021 and the Educational Day on October 23, 2021. Education, scientific research and development must continue! And therefore, EANO remains fully committed to deliver high quality content and state of the art lectures, but this year in an online conference format.

On behalf of the EANO board,

Matthias Preusser
EANO President

and

Martin van den Bent
EANO Past-President



Matthias Preusser
EANO President



Martin van den Bent
EANO Past-President



BOARD, COMMITTEES AND ORGANISATION

EANO Executive Board

President:

Matthias Preusser, Austria

Past President:

Martin van den Bent, Netherlands (EANO 2021 Meeting President, Chair EANO Guidelines Committee)

Board Members:

Anthony Chalmers, United Kingdom
Asgeir Jakola, Sweden
Simone Niclou, Luxembourg
Karin Piil, Denmark (Nurse and Allied Health Professionals Representative)
Patrick Roth, Switzerland
Roberta Rudà, Italy (Treasurer)
Felix Sahn, Germany
Marilena Theodorou, Cyprus

EANO Scientific Committee

Chair:

Michael Platten, Germany

Next-Chair:

Manuel Valiente, Spain

Members:

Florien Willemijn Boele, United Kingdom
Antonella Castellano, Italy
Elizabeth Cohen-Jonathan Moyal, France
Pim French, Netherlands
Oliver Hanemann, United Kingdom
Darren Hargrave, United Kingdom
Benedikte Hasselbalch, Denmark
Asgeir Jakola, Sweden
Tareq Juratli, Germany
Christian Mawrin, Germany
Federico Pessina, Italy
Matthias Preusser, Austria
Martin van den Bent, Netherlands
Jan-Michael Werner, Germany (Youngsters Representative)

EANO General Board

Co-Opted Board Members:

Anna Berghoff, Austria (Chair EANO Youngsters Committee)
Evangelia Razis, Greece (Chair EANO Educational Committee)
Michael Platten, Germany (Chair EANO Scientific Committee)
Wolfgang Wick, Germany (Chair EANO Publishing Activity Committee)

EANO Educational Committee

Chair:

Evangelia Razis, Greece

Next-Chair:

Stephen Price, United Kingdom

Members:

Riccardo Soffietti, Past-Chair, Italy
Vera Lúcia Espírito Santo Barbosa, Spain
Helen Bulbeck, United Kingdom
Mihaela Lorger, Slovenia/United Kingdom
Simone Niclou, Luxembourg
Claudia Panciroli, Italy/Spain
George Petrescu, Romania (Youngster Representative)
Karin Piil, Denmark
Marco Riva, Italy
Maria Angeles Vaz Salgado, Portugal



EANO Office

Wiener Medizinische Akademie GmbH
Ms. Alissa McGregor
Alser Strasse 4
1090 Vienna, Austria
ZVR-Nr: 1354341315
T: +43 1 405 13 83 41
F: +43 1 405 13 83 941
E: office@eano.eu
W: www.eano.eu

EANO 2021 Conference Organisation

Scientific Management, Exhibition and Sponsorship, General Organisation and Logistics

Wiener Medizinische Akademie GmbH
Ms. Lydia Schnedl
Mr. Julian Piskula
Alser Strasse 4
1090 Vienna, Austria
T: +43 1 405 13 83 14
F: +43 1 405 1383 9 14
E: eano-meetings@eano.eu
W: www.eano.eu/eano2021



ACCREDITATION

CME CREDITS EANO Meeting 2021

The 16th Meeting of the European Association of Neuro-Oncology (EANO Meeting 2021), Virtual, Austria, 25/09/2021-26/09/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



CME CREDITS EANO Educational Day 2021

The EANO Educational Day 2021, Vienna, Austria, 23/10/2021-23/10/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME® credits

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

CME CERTIFICATE/CONFIRMATION OF ATTENDANCE

Participants will be able to download their CME Certificate after completion of the post-congress survey.

Confirmations of attendance will be issued electronically via email after the conference to all participants.

FUTURE MEETINGS

EANO 2022	September 15-18, 2022 Hofburg Vienna, Vienna (AUSTRIA)
EANO 2023	September 21-24, 2023 De Doelen, Rotterdam (NETHERLANDS)
EANO 2024	October 17-20, 2024 Scottish Event Campus, Glasgow (UNITED KINGDOM)

More information will be available online at www.eano.eu closer to the conferences.



SCIENTIFIC PROGRAMME & INFORMATION

Scientific Programme & Information	7
EANO Meeting - Programme at a Glance	8
EANO Meeting – Saturday, September 25, 2021	10
EANO Meeting – Sunday, September 26, 2021	13
EANO Meeting – On-demand	18
E-Poster viewing with authors	20
EANO Educational Day – Programme at a Glance	21
EANO Educational Day – Saturday, October 23, 2021	22
EANO Educational Day – On-demand	24
Virtual Conference Format	25
Live Sessions	25
On-demand Sessions	25
E-Poster	25



EANO MEETING - PROGRAMME AT A GLANCE

	Saturday, September 25		
	EANO Meeting		
Times	LIVE CHANNEL 1	LIVE CHANNEL 2	LIVE CHANNEL 3
08:30-08:45			
08:45-09:00			
09:00-09:15	09:00-10:00	09:00-10:00	09:00-10:00
09:15-09:30	Joint Session 1: CSNO-EANO	Oral Session 1: EANO Disparity	Workshop 1: Radiobiology
09:30-09:45	Youngsters	Committee	
09:45-10:00			
10:00-10:15	10:00-10:30		
10:15-10:30	Break		
10:30-10:45	10:30-12:00	10:30-12:00	10:30-12:00
10:45-11:00	Keynote Session 1: The differential	Oral Session 2: Impact of tumor	Oral Session 3: Exploring new
11:00-11:15	immune landscape in between	plasticity on experimental therapies	radiation therapy technologies
11:15-11:30	primary and secondary brain tumors		
11:30-11:45			
11:45-12:00			
12:00-12:15	12:00-12:30		
12:15-12:30	Break		
12:30-12:45	12:30-13:30	12:30-13:30	
12:45-13:00	Corporate Symposium	Corporate Symposium	
13:00-13:15			
13:15-13:30			
13:30-13:45	13:30-14:00		
13:45-14:00	Break		
14:00-14:15	14:00-14:45		
14:15-14:30	E-Poster Viewing with authors		
14:30-14:45	Topic 1-12		
14:45-15:00			
15:00-15:15	15:00-16:00	15:00-16:00	15:00-16:00
15:15-15:30	Meet the Experts 1: Rare tumors:	Meet the Experts 2: Neurosurgical	Workshop 2: EANO Youngsters: End of
15:30-15:45	EURACAN	precision tools	life discussion in Neuro-Oncology
15:45-16:00			
16:00-16:15	16:00-16:30		
16:15-16:30	Break		
16:30-16:45	16:30-18:00		
16:45-17:00	Plenary 2: New Molecular Insights		
17:00-17:15			
17:15-17:30			
17:30-17:45			
17:45-18:00			
18:00-18:15	18:00-18:30		
18:15-18:30	Break		
18:30-18:45	18:30-20:00	18:30-20:00	18:30-20:00
18:45-19:00	Joint Session 2: EANM-EANO: New	Joint Session 3: SNO-EANO: Studies	Joint Session 4: EANS-EANO:
19:00-19:15	developments in imaging tracers	that changed concepts	Surgery versus other treatment
19:15-19:30	and beyond		options in progressive disease
19:30-19:45			
19:45-20:00			
20:00-20:15			
20:15-20:30			



	Sunday, September 26				
	EANO Meeting				
Times	LIVE CHANNEL 1	LIVE CHANNEL 2	LIVE CHANNEL 3		
08:30-08:45					
08:45-09:00					
09:00-09:15	09:00-10:30 Oral Session 4: EANO Youngsters: The next generation glioblastoma trials				
09:15-09:30					
09:30-09:45		09:30-10:30 Plenary 3: Award Winning Abstracts	09:30-10:30 Meet the Experts 3: Brain imaging		
09:45-10:00					
10:00-10:15					
10:15-10:30					
10:30-10:45	10:30-11:00				
10:45-11:00	Break				
11:00-11:15	11:00-12:30 Oral Session 5: Highlights from clinical abstracts	11:00-12:30 Oral Session 6: Highlights from preclinical abstracts	11:00-12:30 Oral Session 7: Cognition in brain tumors revisited: new technologies to improve outcome		
11:15-11:30					
11:30-11:45					
11:45-12:00					
12:00-12:15					
12:15-12:30					
12:30-12:45	12:30-14:45 EANO Youngsters Networking Event	12:30-14:45 Break			
12:45-13:00					
13:00-13:15					
13:15-13:30					
13:30-13:45					
13:45-14:00					
14:00-14:15	14:00-14:45				
14:15-14:30	E-Poster Viewing with authors				
14:30-14:45	Topic 13-16				
14:45-15:00					
15:00-15:15	15:00-16:00 Pro & Con Session 1: BBB in brain tumors: compromised or maintained	15:00-16:00 Workshop 3: EANO Youngsters Mentoring	15:00-16:00 Workshop 4: scRNAseq: new techniques and implications		
15:15-15:30					
15:30-15:45					
15:45-16:00					
16:00-16:15	16:00-16:30				
16:15-16:30	Break				
16:30-16:45	16:30-18:00 Keynote Session 2: Targeting aberrant DNA damage response phenotypes in glioma	16:30-18:00 Oral Session 8: Multilayer diagnostics	16:30-18:00 Joint Session 5: EAN-EANO		
16:45-17:00					
17:00-17:15					
17:15-17:30					
17:30-17:45					
17:45-18:00					
18:00-18:15	18:00-18:30				
18:15-18:30	Break				
18:30-18:45	18:30-19:30 Meet the Experts 4: Patient experience/involvement	18:30-19:30 Meet the Experts 5: Tumor heterogeneity	18:30-19:30 Meet the Experts 6: Modeling disease in a dish and its potential for drug screens		
18:45-19:00					
19:00-19:15					
19:15-19:30					
19:30-19:45					
19:45-20:00					

ON-DEMAND	
EANO Meeting	
always available	
ON-DEMAND	Oral Session 9: Quality of life
ON-DEMAND	Oral Session 10: Symptom management
ON-DEMAND	Oral Session 11: Cellular origins of childhood brain tumors
ON-DEMAND	Oral Session 12: Rationalizing combination partners of immunotherapies
ON-DEMAND	Oral Session 13: Genome editing strategies for modelling brain tumors in mice
ON-DEMAND	Oral Session 14: Extent of resection
ON-DEMAND	Joint Session 6: Progress in neuro-oncology (EORTC BTG)



EANO MEETING – SATURDAY, SEPTEMBER 25, 2021

09:00-10:00 Joint Session 1 (JS01): CSNO-EANO Youngsters

Chairs: Alessia Pellerino, *Italy* & George Petrescu, *Romania*

- 09:00-09:15 **JS01.1 Potential target for glioblastoma treatment through understanding microcirculation patterns**
Zhongping Chen, *China*
- 09:15-09:22 **JS01.2.A Oncogenic Chaperoning of Hsp90 in Glioma with FGFR3-TACC3**
Tao Li, *China*
- 09:22-09:30 **JS01.3.A Conventional MRI criteria differentiate true tumour progression from treatment-induced effects in irradiated WHO grade 3 and 4 gliomas**
Christina Flies, *Netherlands*
- 09:30-09:45 **JS01.4 Surgery or chemotherapy in lower-grade glioma?**
Amélie Darlix, *France*
- 09:45-09:52 **JS01.5.A The neurocognitive function changes with awake craniotomy for low grade glioma in the left hemispheric eloquent regions**
Yuan Wang, *China*
- 09:52-10:00 **JS01.6.A Adjuvant treatment versus initial observation in newly diagnosed WHO grade II and grade III oligodendroglioma: real-life data from two academic, tertiary care centers in Austria**
Maximilian Mair, *Austria*

09:00-10:00 Oral Session 1 (OS01): EANO Disparity Committee

Chair: Emilie Le Rhun, *France*

- 09:00-09:30 **OS01.1 Women's perspective**
Ghazaleh Tabatabai, *Germany*
Estela Pineda, *Spain*
Susan Short, *United Kingdom*
Karin Piil, *Denmark*
Julia Furtner-Srajer, *Austria*
- 09:30-10:00 **OS01.2 Disparity of care**
Bozena Kaminska, *Poland*
Tomas Kazda, *Czech Republic*
Pieter Wesseling, *Netherlands*
Simone Niclou, *Luxembourg*
Maciej Mrugala, *United States*

09:00-10:00 Workshop 1 (WS01): Radiobiology

Chairs: Elizabeth Cohen-Moyal, *France* & Anthony Chalmers, *United Kingdom*

- 09:00-09:20 **WS01.1 Optimizing radiotherapy using Nanoparticles**
Karl Butterworth, *United Kingdom*
- 09:20-09:40 **WS01.2 Intrinsic radioresistance and FGFR pathway**
Elizabeth Cohen-Moyal, *France*
- 09:40-10:00 **WS01.3 Aberrant DNA repair as a therapeutic target in glioblastoma**
Petra Hamerlik, *Denmark*

10:00-10:30 BREAK

10:30-12:00 Keynote Session 1 (KS01): The differential immune landscape in between primary and secondary brain tumors

Chairs: Mihaela Lorger, *United Kingdom* & Michael Platten, *Germany*

- 10:30-10:55 **KS01.1 Acquired immune system (T cells)**
Burkhard Becher, *Switzerland*
- 10:55-11:20 **KS01.2 Exploring and Therapeutically Exploiting the Brain Tumour Microenvironment**
Johanna Joyce, *Switzerland*



11:20-11:30	KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion Yu-Chan Chih, <i>Germany</i>
11:30-11:40	KS01.4.A NK cells as key orchestrators in mediating the anti-tumour response to immune checkpoint blockade in melanoma brain metastases Christopher Fife, <i>United Kingdom</i>
11:40-11:50	KS01.5.A Allergic airway inflammation impacts tumor take and delays experimental glioblastoma progression Aurélie Poli, <i>Luxembourg</i>
11:50-12:00	KS01.6.A Comparative analysis of the immune compartment in human glioblastoma and IDH-mutant WHO grade 4 astrocytoma reveals profound differences in microglia phenotypes Roman Sankowski, <i>Germany</i>
10:30-12:00	Oral Session 2 (OS02): Impact of tumor plasticity on experimental therapies Chairs: Oliver Hanemann, <i>United Kingdom</i> & Matthias Preusser, <i>Austria</i>
10:30-10:50	OS02.1 Impact of tumor plasticity on experimental therapies for brain metastases Manuel Valiente, <i>Spain</i>
10:50-11:10	OS02.2 Tumor plasticity from a neurosurgical perspective Colin Watts, <i>United Kingdom</i>
11:10-11:30	OS02.3 Your viewpoint on the impact of tumor heterogeneity on experimental therapies Wolfgang Wick, <i>Germany</i>
11:30-11:40	OS02.4.A Molecular characterization of adult cerebellar glioblastomas identifies distinct prognosis subgroups Thiébaud Picart, <i>France</i>
11:40-11:50	OS02.5.A Glioblastoma Metabolic Symbiosis : When Lactate Takes The Lead. Thomas Daubon, <i>France</i>
11:50-12:00	OS02.6.A The TeloDIAG : How telomeric parameters can help in glioma rapid diagnosis and liquid biopsies approaches Delphine Poncet, <i>France</i>
10:30-12:00	Oral Session 3 (OS03): Exploring new radiation therapy technologies Chairs: Elizabeth Cohen-Moyal, <i>France</i> & Anthony Chalmers, <i>United Kingdom</i>
10:30-10:55	OS03.1 Carbon ion therapy for brain tumours in theory and in practice Stephanie Combs, <i>Germany</i>
10:55-11:20	OS03.2 Proton beam therapy for adult central nervous system tumours: pros and cons Gillian Whitfield, <i>United Kingdom</i>
11:20-11:30	OS03.3.A Characterization of long-term metabolic changes of irradiated brain metastases using serial dynamic FET PET imaging Norbert Galldiks, <i>Germany</i>
11:30-11:40	OS03.4.A Irradiation of the subventricular and subgranular zone and overall survival in high-grade glioma patients Danique Bruil, <i>Netherlands</i>
11:40-11:50	OS03.5.A Corelation between longitudinal t2 MRI radiomic primary texture feature values and radiation dose in non-tumoral regions of the brain in paediatric brain tumours Priyanka Sakhavalkar, <i>United Kingdom</i>
12:00-12:30	BREAK
12:30-13:30	Corporate Symposia
13:30-14:00	BREAK
14:00-14:45	E-Poster Viewing with authors
14:45-15:00	BREAK



15:00-16:00

Meet the Experts 1 (ME01): Rare tumors: EURACAN

Chairs: Roberta Rudà, *Italy* & Martin van den Bent, *Netherlands*

15:00-15:20

ME01.1 Medulloblastoma: a multicenter trial in adult patients

Peter Hau, *Germany*

15:20-15:40

ME01.2 EURACAN and CNS tumors: background of the effort

Ahmed Idbaih, *France*

15:40-16:00

ME01.3 NTRK fusions and glioma

Evangelia Razis, *Greece*

15:00-16:00

Meet the Experts 2 (ME02): Neurosurgical precision tools

Chairs: Gelareh Zadeh, *Canada* & Asgeir Jakola, *Sweden*

15:00-15:20

ME02.1 Continuous dynamic mapping for removal of brain tumors in eloquent brain regions

Kathleen Seidel, *Switzerland*

15:20-15:40

ME02.2 Laser ablation - Indications in Neuro-oncology

Mark ter Laan, *Netherlands*

15:40-16:00

ME02.3 Integrated Classification of Meningiomas

Gelareh Zadeh, *Canada*

15:00-16:00

Workshop 2 (WS02): EANO Youngsters: End of life discussion in Neuro-Oncology

Chairs: Marjolein Geurts, *Netherlands* & Simona Gaito, *United Kingdom*

15:00-15:30

WS02.1 You cannot not communicate

Eva Masel, *Austria*

15:30-16:00

WS02.2 Palliative care and end-of-life management in brain tumors

Andrea Pace, *Italy*

16:00-16:30

BREAK

16:30-18:00

Plenary 2 (PL02): New Molecular Insights

Chairs: Simone Niclou, *Luxembourg* & Pim French, *Netherlands*

16:30-16:55

PL02.1 Cancer dependency maps

Mathew Garnett, *United Kingdom*

16:55-17:20

PL02.2 Exceptional Responders: Inferences from N of 1 Experiments

David Wheeler, *United States*

17:20-17:30

PL02.3.A Phenotypic heterogeneity and plasticity as resistance mechanisms in Glioblastoma

Anna Golebiewska, *Luxembourg*

17:30-17:40

PL02.4.A Chromosome 1p19q codeletion frequency, but not survival, varies according to the IDH mutation subtypes: analysis of 1050 IDH-mutated diffuse gliomas.

Alberto Picca, *France*

17:40-17:50

PL02.5.A The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.

Giuseppe Lombardi, *Italy*

18:00-18:30

BREAK

18:30-20:00

Joint Session 2 (JS02): EANM-EANO: New developments in imaging tracers and beyond

Chairs: Antonella Castellano, *Italy* & Patrick Roth, *Switzerland*

18:30-18:55

JS02.1 Treatment Monitoring in Brain tumors: New Insights by Amino Acid PET, „ImmunoPET“ and PET Radiomics?

Norbert Galldiks, *Germany*



18:55-19:20 **JS02.2 TSPO – a new tracer for imaging glioma and microglia**

Jörg Tonn, *Germany*

19:20-19:45 **JS02.3 Radiolabelled compounds as theranostics of brain tumors**

Tatjana Traub-Weidinger, *Austria*

18:30-20:00 Joint Session 3 (JS03): SNO-EANO: Studies that changed concepts

Chairs: Susan Chang, *United States* & Wolfgang Wick, *Germany*

18:30-18:50 **JS03.1 Evidence based: 6 cycles of adjuvant temozomide suffices in glioblastoma**

Carmen Balanà Quintero, *Spain*

18:50-19:10 **JS03.2 IDH inhibitors: early signs of activity?**

Ingo Mellinghoff, *United States*

19:10-19:30 **JS03.3 Detection and discrimination of intracranial tumors by blood**

Farshad Nassiri, *Canada*

19:30-19:50 **JS03.4 Synaptic communication in brain tumours**

Varun Venkataramani, *Germany*

18:30-20:00 Joint Session 4 (JS04): EANS-EANO: Surgery versus other treatment options in progressive disease

Chairs: Marike Broekman, *Netherlands* & Martin van den Bent, *Netherlands*

18:30-18:50 **JS04.1 When and why to perform repeated surgery for progressive LGG**

Lorenzo Bello, *Italy*

18:50-19:10 **JS04.2 Systemic therapies for intracranial metastasis, what are the options and when to refer for local therapy?**

Anna Berghoff, *Austria*

19:10-19:30 **JS04.3 Neurosurgical and radiosurgical decision making in patients with brain metastases in the era of personalized medicine**

Philippe Métellus, *France*

19:30-19:50 **JS04.4 Oncological treatment in progressive LGG following surgery - or should all be treated upfront?**

Martin van den Bent, *Netherlands*

EANO MEETING – SUNDAY, SEPTEMBER 26, 2021

09:00-10:30 Oral Session 4 (OS04): EANO Youngsters Committee: The next generation glioblastoma trials

Chairs: Anna Berghoff, *Austria* & Jan-Michael Werner, *Germany*

09:00-09:15 **OS04.1 New therapies under investigation: What is TG02?**

Emilie Le Rhun, *France*

09:15-09:30 **OS04.2 Targets in Neuro-Oncology - What should we investigate next?**

Simone Niclou, *Luxembourg*

09:30-09:45 **OS04.3 New therapies under investigation: What is Marizomib?**

Patrick Roth, *Switzerland*

09:45-10:00 **OS04.4 Pitfalls in clinical trials design**

Michael Weller, *Switzerland*

09:30-10:30 Plenary 3 (PL03): Award Winning Abstracts

Chairs: Claudia Panciroli, *Spain* & Manuel Valiente, *Spain*

09:30-09:45 **PL03.1.A Surgery for glioblastomas in the elderly: an ANOCEF trial (CSA)**

Florence Laigle-Donadey, *France*

EANO Congress Award - Best oral presentation: Clinical research (*kindly supported by Vienna Medical Academy*)



09:45-10:00	<p>PL03.2.A Radiotherapy is associated with a deletion signature that contributes to poor outcomes in glioma patients Emre Kocakavuk, <i>United States</i> EANO Congress Award - Best oral presentation: Basic research</p>
10:00-10:15	<p>PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma Lena Hänsch, <i>Switzerland</i> EANO Congress Award - Best oral presentation: Translational research</p>
10:15-10:30	<p>PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period Marijke Coomans, <i>Netherlands</i> EANO Congress Award - Best oral presentation: Supportive care and quality of life research</p>
09:30-10:30	<p>Meet the Experts 3 (ME03): Brain imaging</p> <p>Chairs: Antonella Castellano, <i>Italy</i> & Marilena Theodorou, <i>Cyprus</i></p>
09:30-09:50	<p>ME03.1 Heterogeneity and microstructure models with diffusion MRI Eleftheria Panagiotaki, <i>United Kingdom</i></p>
09:50-10:10	<p>ME03.2 Experimental new imaging in brain metastasis and translation to patients Fabien Boux, <i>France</i></p>
10:10-10:30	<p>ME03.3 Radiomics and AI in brain tumor imaging Philipp Vollmuth, <i>Germany</i></p>
10:30-11:00	<p>BREAK</p>
11:00-12:30	<p>Oral Session 5 (OS05): Highlights from clinical abstracts</p> <p>Chairs: Emilie Le Rhun, <i>France</i> & Susan Short, <i>United Kingdom</i></p>
11:00-11:10	<p>OS05.1.A Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) Matthias Preusser, <i>Austria</i></p>
11:10-11:20	<p>OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group C. Mircea S. Tesileanu, <i>Netherlands</i></p>
11:20-11:30	<p>OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials Julia Furtner-Srajer, <i>Austria</i></p>
11:30-11:40	<p>OS05.4.A Do neurocognitive deficits explain the differences between brain tumour patients and their proxies assessing the patient's I-ADL? Quirien Oort, <i>Netherlands</i></p>
11:40-11:50	<p>OS05.5.A Methylation analysis of matched primary and recurrent IDHmt astrocytoma; an update from the Glioma Longitudinal Analysis NL (GLASS-NL) consortium Wies Vallentgoed, <i>Netherlands</i></p>
11:50-12:00	<p>OS05.6.A Detection and serial monitoring of ctDNA in breast cancer leptomeningeal disease Amanda Fitzpatrick, <i>United Kingdom</i></p>
12:00-12:10	<p>OS05.7.A Absence of severe hematological toxicity during first line treatment predicts low chance on severe toxicity during second line alkylating chemotherapy in glioblastoma Femke van den Elzen, <i>Netherlands</i></p>
12:10-12:20	<p>OS05.8.A A Phase 0/1 'Trigger' Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma Nader Sanai, <i>United States</i></p>
12:20-12:30	<p>OS05.9.A Short-term fasting in glioma patients - Analysis of diet diaries and metabolic parameters of the ERGO2 trial Martin Voss, <i>Germany</i></p>



11:00-12:30

Oral Session 6 (OS06): Highlights from preclinical abstracts

Chairs: Mihaela **Lorger**, *United Kingdom* & Michael **Weller**, *Switzerland*

11:00-11:10

OS06.1.A non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Pim **French**, *Netherlands*

11:10-11:20

OS06.2.A Local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells

Michael **Burger**, *Germany*

11:20-11:30

OS06.3.A LSD1-directed therapy curtails glioblastoma tumorigenicity by limiting the adaptation of tumor initiating cells to stressful environments

Stefania **Faletti**, *Italy*

11:30-11:40

OS06.4.A Identification of T cell receptors targeting ZFTA-RELA fusion-positive ependymoma

Niklas **Kehl**, *Germany*

11:40-11:50

OS06.5.A Fluorescence image-guided resection of intracranial meningioma: an experimental in vivo study on nude mice

Stefan **Linsler**, *Germany*

11:50-12:00

OS06.6.A Inhibition of GBM invasion by the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist Perampanel

Katharina **Sarnow**, *Norway*

12:00-12:10

OS06.7.A METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy

Lucia **Zhu**, *Spain*

12:10-12:20

OS06.8.A Circulating extracellular vesicles as a novel tool for therapy monitoring of brain tumor patients

Franz **Ricklefs**, *Germany*

12:20-12:30

OS06.9.A Diversity of cellular communication in glioblastoma

Kevin **Joseph**, *Germany*

11:00-12:30

Oral Session 7 (OS07): Cognition in brain tumors revisited: new technologies to improve outcome

Chairs: Djaina **Satoer**, *Netherlands* & Martin **Klein**, *Netherlands*

11:00-11:20

OS07.1 Functional Ultrasound: the new gold standard to measure language functions during awake brain surgery?

Ellen **Collée**, *Netherlands*

11:20-11:40

OS07.2 Trial results of ReMind: the app for cognition rehabilitation in primary brain tumor patients

Karin **Gehring**, *Netherlands*

11:40-12:00

OS07.3 Ready, Set, Shift: intraoperative mapping of concept-shifting improves outcome

Emmanuel **Mandonnet**, *France*

12:00-12:20

OS07.4 Guess where? Mapping the cognitive interface via invasive and non-invasive imaging techniques

Constanza **Papagno**, *Italy*

12:20-12:30

OS07.5.A Diagnostic Instrument for Mild Aphasia (DIMA): sensitive and valuable addition to standard language assessment in glioma patients

Saskia **Mooijman**, *Netherlands*

12:30-14:00

BREAK

12:30-14:45

EANO Youngsters Networking Event

14:00-14:45

E-Poster Viewing with authors

14:45-15:00

BREAK



15:00-16:00 Pro & Con Session 1 (PC01): BBB in brain tumors: compromised or maintained

Chairs: Manuel Valiente, *Spain* & Patrick Roth, *Switzerland*

15:00-15:15 PC01.1 BBB/BBB in brain tumors (Maintained)

Patricia Steeg, *United States*

15:15-15:30 PC01.2 Compromised blood-brain-barrier

Patrick Wen, *United States*

15:00-16:00 Workshop 3 (WS03): EANO Youngsters Mentoring

WS03.1 How to plan your career in neuro-oncology: Neurosurgery

Marieke Broekman, *Netherlands*

WS03.2 How to plan your career in neuro-oncology: Neuroradiology

Antonella Castellano, *Italy*

WS03.3 How to plan your career in neuro-oncology: Basic/Translational Research

Pim French, *Netherlands*

WS03.4 How to plan your career in neuro-oncology: Computational Imaging Research

Georg Langs, *Austria*

WS03.5 How to plan your career in neuro-oncology: Pediatric neuro-oncology

Sabine Müller, *United States*

WS03.6 How to plan your career in neuro-oncology: Clinical neuro-oncology

Roberta Rudà, *Italy*

15:00-16:00 Workshop 4 (WS04): scRNAseq: new techniques and implications

Chairs: Simone Niclou, *Luxembourg* & Felix Sahm, *Germany*

15:00-15:30 WS04.1 Atlas of spatially resolved multiomics in malignant brain tumours

Dieter Henrik Heiland, *Germany*

15:30-16:00 WS04.2 scRNAseq and progenitor diversity in glioma

Q. Richard Lu, *United States*

16:00-16:30 BREAK

16:30-18:00 Keynote Session 2 (KS02): Targeting aberrant DNA damage response phenotypes in glioma

Chairs: Roberta Rudà, *Italy* & Wolfgang Wick, *Germany*

16:30-16:55 KS02.1 A novel prognostic and predictive DNA repair gene expression signature in glioblastoma

Mary-Helen Barcellos-Hoff, *United States*

16:55-17:20 KS02.2 DNA repair vulnerabilities in IDH mutant gliomas

Ranjit Bindra, *United States*

17:20-17:45 KS02.3 Clinical trials targeting the DNA damage response in glioma

Anthony Chalmers, *United Kingdom*

17:45-17:55 KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)

Francois Ducray, *France*

16:30-18:00 Oral Session 8 (OS08): Multilayer diagnostics

Chairs: Oliver Hanemann, *United Kingdom* & Tobias Weiss, *Switzerland*

16:30-16:50 OS08.1 MR Spectroscopy for brain glioma diagnosis and therapeutic assessment

Francesca Branzoli, *France*

16:50-17:10 OS08.2 Integrated intraoperative diagnosis of brain tumors

Daniel Orringer, *United States*

17:10-17:30 OS08.3 Proteomics for brain tumor diagnosis

Andreas von Deimling, *Germany*



17:30-17:40	OS08.4.A Retrospective analysis of in vivo 1H-magnetic resonance spectroscopy based on a machine learning approach enables reliable prediction of IDH mutation in patients with glioma Elisabeth Bumès, <i>Germany</i>
17:40-17:50	OS08.5.A Proteomic analysis of meningioma Clemens Hanemann, <i>United Kingdom</i>
17:50-18:00	OS08.6.A Glioblastoma treatment response machine learning monitoring biomarkers: a systematic review and meta-analysis Aysha Luis, <i>United Kingdom</i>
16:30-18:00	Joint Session 5 (JS05): EAN-EANO Chairs: Jérôme Honnorat, <i>France</i> & Riccardo Soffietti, <i>Italy</i>
16:30-16:50	JS05.1 Sex-based differences in Neuro-Oncology Jill Barnholtz-Sloan, <i>United States</i>
16:50-17:10	JS05.2 Phase 0 and Window-of-Opportunity Trials in Neuro-Oncology Susan Chang, <i>United States</i>
17:10-17:30	JS05.3 Discovery of tumor-reactive T cells in Neuro-Oncology Michael Platten, <i>Germany</i>
17:30-17:50	JS05.4 Circulating Tumor DNA in Neuro-Oncology Joan Seoane, <i>Spain</i>
18:00-18:30	BREAK
18:30-19:30	Meet the Experts 4 (ME04): Patient experience/involvement Chairs: Karin Piil, <i>Denmark</i> & Kathy Oliver, <i>United Kingdom</i>
18:30-18:50	ME04.1 What can the wider community learn from people living with brain cancer during COVID? Helen Bulbeck, <i>United Kingdom</i>
18:50-19:10	ME04.2 The Brain Tumour Patients' Charter of Rights Kathy Oliver, <i>United Kingdom</i>
19:10-19:30	ME04.3 Brain tumours and COVID-19: the patient and caregiver experience Mathew Voisin, <i>Canada</i>
18:30-19:30	Meet the Experts 5 (ME05): Tumor heterogeneity Chairs: Elizabeth Cohen-Moyal, <i>France</i> & Manuel Valiente, <i>Spain</i>
18:30-18:50	ME05.1 Clinical implications of brain metastasis heterogeneity Priscilla Brastianos, <i>United States</i>
18:50-19:10	ME05.2 Mouse models of glioma heterogeneity Dolores Hambardzumyan, <i>United States</i>
19:10-19:30	ME05.3 Dissecting response to treatment in adult patients with a glioma Roel Verhaak, <i>United States</i>
18:30-19:30	Meet the Experts 6 (ME06): Modeling disease in a dish and its potential for drug screens Chairs: Anna Golebiewska, <i>Luxembourg</i> & Tobias Weiss, <i>Switzerland</i>
18:30-18:50	ME06.1 Organotypic brain tumor cultures Simone Niclou, <i>Luxembourg</i>
18:50-19:10	ME06.2 3D-bioprinted models of brain tumors Ronit Satchi-Fainaro, <i>Israel</i>
19:10-19:30	ME06.3 A patient-derived glioblastoma organoid model recapitulates inter- and intra-tumoral heterogeneity Hongjun Song, <i>United States</i>



EANO MEETING – ON-DEMAND

Oral Session 9 (OS09): Quality of life

Intro: Federico Pessina, *Italy*

OS09.1 Quality of life in follow-up (of adults)

Florien Boele, *United Kingdom*

OS09.2 Quality of life in follow-up (of children)

Kim Bull, *United Kingdom*

OS09.3.A Caregiver burden of glioma patients: the impact of informal care

Robin van den Borg, *Netherlands*

OS09.4.A Health-related quality of life in low-grade glioma survivors 26 years after diagnosis

Florien Boele, *United Kingdom*

OS09.6.A Cognition and health-related quality of life in long time survivors of high-grade glioma

Marieke Donders-Kamphuis, *Netherlands*

OS09.7.A Quality of life outcomes in patients with incidental and operated meningiomas: the QUALMS study

Sumirat Keshwara, *United Kingdom*

Oral Session 10 (OS10): Symptom management

Intro: Florian Boele, *United Kingdom*

OS10.1 Symptom Management Models and Non-pharmacological Symptom Management

Karin Piil, *Denmark*

OS10.2 Pharmacological management of symptoms after a brain tumour: Opening a psychiatrist's medicine box

Ally Rooney, *United Kingdom*

OS10.3.A Predicting delirium after craniotomy in neuro-oncology

Pablo Kappen, *Netherlands*

OS10.4.A The effects of SmartCare on neuro-oncology family caregivers' distress: a randomized controlled trial

Paula Sherwood, *United States*

OS10.5.A BrainWear: Longitudinal, objective assessment of physical activity in 42 HGG patients

Seema Dadhania, *United Kingdom*

OS10.6.A Supportive care needs of TYA childhood brain tumour survivors and their caregivers: a mixed methods study

Emma Nicklin, *United Kingdom*

OS10.7.A Localization patterns of language errors during direct electrical brain stimulation: a systematic review

Ellen Collée, *Netherlands*

OS10.8.A The effectiveness of antiepileptic drug duotherapies in glioma patients: a multicenter observational cohort study

Pim van der Meer, *Netherlands*

Oral Session 11 (OS11): Cellular origins of childhood brain tumors

Intro: Stefan Pfister, *Germany*

OS11.1 Dereglulation of chromatin modifier genes in medulloblastoma

Silvia Marino, *United Kingdom*

OS11.2 H3.3G34 mutations in gliomas: a case of mistaken identity

Nada Jabado, *Canada*

OS11.3 Modeling childhood brain tumors in vivo and with human organoids

Luca Tiberi, *Italy*

OS11.4 Developmental myelination and the origins of H3K27M+ diffuse midline glioma

Michelle Monje Deisseroth, *United States*

OS11.5.A PATZ1 fusions define a novel molecularly distinct CNS tumor entity with a broad histological spectrum

Karam Al Halabi, *Germany*



Oral Session 12 (OS12): Rationalizing combination partners of immunotherapies

Intro: Benedikte Hasselbalch, *Denmark*

OS12.1 First in human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) clinical trial in patients with recurrent high-grade glioma shows immunologic changes in injected tumors

E. Antonio Chiocca, *United States*

OS12.2 Combination of vaccines with checkpoint inhibitors for the treatment of brain tumors

Valerie Dutoit, *Switzerland*

OS12.3 Combining immune checkpoint inhibitors with stereotactic radiosurgery: is it safe and does it work?

Giuseppe Minniti, *Italy*

OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas

Michael Kilian, *Germany*

OS12.5.A The combination of the oncolytic virus Delta-24-ACT with a PD-L1 inhibitor results in anti-glioma effect and immune memory in preclinical models of glioma

Montse Puigdelloses, *Spain*

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Michael Burger, *Germany*

OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level

Christina Blume, *Germany*

Oral Session 13 (OS13): Genome editing strategies for modelling brain tumors in mice

Intro: Christian Mawrin, *Germany*

OS13.1 In-vivo electroporation to dissect the biology of brain tumours

Paolo Salomoni, *Germany*

OS13.2 Modelling brain tumours one base at a time

Massimo Squatrito, *Spain*

OS13.3.A Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma

Francesco Antonica, *Italy*

Oral Session 14 (OS14): Extent of resection

Intro: Tareq Juratli, *Germany*

OS14.1 Residual tumor following resection of brain metastasis and the role of fluorescence

Barbara Kiesel, *Austria*

OS14.2 The evidence and safety of supramarginal resection in patient with glioblastoma

Frederico Pessina, *Italy*

OS14.3 Beyond grey scale B-mode ultrasound imaging to maximize the extent of resection

Francesco Prada, *Italy*

OS14.4.A The Neuroplastic Potential of the Human Brain Before and After Glioma Surgery: Towards Interventional Neurorehabilitation

Anujan Poologaindran, *United Kingdom*

OS14.5.A 3D high-resolution 7T MRSI for the metabolic imaging of high-grade gliomas

Gilbert Hangel, *Austria*

OS14.6.A Gliocova: Defining patient safety events for brain tumour patients undergoing neurosurgery

Radvile Mauricaite, *United Kingdom*

Joint Session 6 (JS06): Progress in neuro-oncology (EORTC BTG)

JS06.1 Overview of EORTC Brain Tumor Group studies

Matthias Preusser, *Austria*



E-POSTER VIEWING WITH AUTHORS

Saturday, September 25, 2021 from 14:00-14:45 • Poster Session I

Poster Topics 1-12

P01 Blood brain barrier/ Blood tumor barrier
P02 Radiobiology
P03 Cognition in brain tumors
P04 Tumor heterogeneity, plasticity and impact on therapeutic response
P05 Radiation technologies
P06 Pediatric brain tumors

P07 Multilayer intra- and postoperative diagnostics and novel imaging technologies
P08 Combined immunotherapies
P09 Imaging strategies to improve neurosurgical outcome
P10 Advanced brain tumor models
P11 QoL/QoD
P12 Symptom management

Sunday, September 26, 2021 from 14:00-14:45 • Poster Session II

Poster Topics 13-16

P13 Preclinical neuro-oncology
P14 Clinical neuro-oncology

P15 DNA damage repair and genomic instability
P16 Brain tumor microenvironment



EANO EDUCATIONAL DAY – PROGRAMME AT A GLANCE

Saturday, October 23			
	EDUCATIONAL DAY		
	Basic	Clinical	Nurses/AHP
Times	LIVE CHANNEL 1	LIVE CHANNEL 2	LIVE CHANNEL 3
09:30-09:45			
09:45-10:00			
10:00-10:15	10:10-11:30 Highlights in clinical science and novel tools	10:10-11:30 Unique clinical issues	
10:15-10:30			
10:30-10:45			10:30-11:30 What matters to patients and their caregivers
10:45-11:00			
11:00-11:15			
11:15-11:30			
11:30-11:45	11:30-12:00 Break		
11:45-12:00			
12:00-12:15	12:00-13:00 Molecular analyses of CNS tumors I	12:00-13:20 Metastatic disease	12:00-13:20 PhD-projects by nurses and AHPs
12:15-12:30			
12:30-12:45			
12:45-13:00			
13:00-13:15	13:00-13:50 Break	13:20-13:50 Break	
13:15-13:30			
13:30-13:45			
13:45-14:00			
14:00-14:15	13:50-14:50 Molecular analyses of CNS tumors II	13:50-14:50 Aya Epidemiologic Spectrum, Late Effects, Psychosocial and end of life care	
14:15-14:30			
14:30-14:45			
14:45-15:00	14:50-15:20 Break		
15:00-15:15			
15:15-15:30	15:20-16:40 Highlights in brain tumor biology	15:20-16:40 New EANO Guidelines	15:20-16:40 The roles of nurses and AHPs in neuro-oncology
15:30-15:45			
15:45-16:00			
16:00-16:15			
16:15-16:30			
16:30-16:45			
16:45-17:00			

ON-DEMAND	
EDUCATIONAL DAY	
always available	
ON-DEMAND	Symptom management and interventions



EANO EDUCATIONAL DAY – SATURDAY, OCTOBER 23, 2021

10:10-11:30

EDB01 | Highlights in clinical science and novel tools

Chairs: Mihaela **Lorger**, *United Kingdom* & Marco **Riva**, *Italy*

10:10-10:30

EDB01.1 CNS taxonomy beyond WHO 2016: Updates on cIMPACT NOW

Dominique **Figarella-Branger**, *France*

10:30-10:50

EDB01.2 Radiomics to aid clinical decision making

Antonella **Castellano**, *Italy*

10:50-11:10

EDB01.3 Artificial intelligence in digital pathology

Jeroen **Van der Laak**, *Netherlands*

11:10-11:30

EDB01.4 Liquid biopsy & Stool microbiome

Andreas **Hottinger**, *Switzerland*

10:10-11:30

EDC01 | Unique clinical issues

Chairs: Annika **Malmström**, *Sweden* & Olivier **Chinot**, *France*

10:10-10:30

EDC01.1 Surgery for intrinsic spinal cord tumours

Claudius **Thomé**, *Austria*

10:30-10:50

EDC01.2 Unique issues in the management of the elderly neuro-oncology patient

Cressida **Lorimer**, *United Kingdom*

10:50-11:10

EDC01.3 Issues in diagnosis: Can advanced imaging techniques aid early diagnosis of true brain tumour progression after treatment?

Esther **Warnert**, *Netherlands*

11:10-11:30

EDC01.4 Second Look surgery in different tumor types

Manfred **Westphal**, *Germany*

10:30-11:30

EDN01 | What matters to patients and their caregivers

Chairs: Helen **Bulbeck**, *United Kingdom* & Lena **Rosenlund**, *Sweden*

10:30-10:50

EDN01.1 Matters to patients and their caregivers and why PROMS are just a small part of the picture

Helen **Bulbeck**, *United Kingdom*

10:50-11:10

EDN01.2 Value based healthcare for neuro-oncology patients: why and how?

Monique **Baas**, *Netherlands*

11:30-12:00

BREAK

12:00-13:00

EDB02 | Molecular analyses of CNS tumors I

Chairs: Katrin **Lamszus**, *Germany* & Rogier **Versteeg**, *Netherlands*

12:00-12:20

EDB02.1 Genetics of Neuroblastoma

Rogier **Versteeg**, *Netherlands*

12:20-12:40

EDB02.2 Epigenetics of Glioma

Sevin **Turcan**, *Germany*

12:40-13:00

EDB02.3 Single cell and spatial transcriptomics

Kiavash **Movahedi**, *Belgium*

12:00-13:20

EDC02 | Metastatic disease

Chairs: Mihaela **Lorger**, *United Kingdom* & Riccardo **Soffietti**, *Italy*

12:00-12:20

EDC02.1 Surgery first

Marco **Riva**, *Italy*

12:20-12:40

EDC02.2 Radiation therapy first

Frédéric **Dhermain**, *France*



12:40-13:00 **EDC02.3 Systemic therapy first**
Evangelia D. Razis, *Greece*

13:00-13:20 **EDC02.4 Brain metastases from CUP**
Anna Berghoff, *Austria*

12:00-13:20 **EDN02 | PhD-projects by nurses and AHPs**

Chairs: Florian Boele, *United Kingdom* & Karin Piil, *Denmark*

12:00-12:20 **EDN02.1 Functional outcome following diagnosis of low-grade glioma**
Isabelle Ryden, *Sweden*

12:20-12:40 **EDN02.2 Language outcome of awake surgery in glioblastoma**
Marieke Donders-Kamphuis, *Netherlands*

12:40-13:00 **EDN02.3 Quality of life in long-term survivorship of primary brain tumours**
Sé Frances, *United Kingdom*

13:00-13:20 **EDN02.4 Patient-reported measures - a patient perspective**
Lena Rosenlund, *Sweden*

13:20-13:50 **BREAK**

13:50-14:50 **EDB03 | Molecular analyses of CNS tumors II**

Chairs: Anna Golebiewska, *Luxembourg* & Manuel Valiente, *Spain*

13:50-14:10 **EDB03.1 Single cell analysis of Ependymoma**
Mariella Filbin, *United States*

14:10-14:30 **EDB03.2 Whole genome projects**
Jason Huse, *United States*

14:30-14:50 **EDB03.3 Molecular Profiling of Brain Metastases**
Priscilla Brastianos, *United States*

13:50-14:50 **EDC03 | Aya Epidemiologic Spectrum, Late Effects, Psychosocial and end of life care**

Chairs: Claudia Panciroli, *Spain* & Martin McCabe, *United Kingdom*

13:50-14:10 **EDC03.1 Epidemiologic spectrum/disease outcomes**
Martin McCabe, *United Kingdom*

14:10-14:30 **EDC03.2 Late CNS radiation & chemotherapy SE (neurocognitive impairments, fertility and endocrinopathies)**
Claudia Panciroli, *Spain*

14:30-14:50 **EDC03.3 Psychosocial and end of life care**
Helen Bulbeck, *United Kingdom*

14:50-15:20 **BREAK**

15:20-16:40 **EDB04 | Highlights in brain tumor biology**

Chairs: Simone Niclou, *Luxembourg* & Pim French, *Netherlands*

15:20-15:40 **EDB04.1 Exploiting experimental models to identify vulnerabilities of brain metastasis**
Manuel Valiente, *Spain*

15:40-16:00 **EDB04.2 Synaptic communication**
Peter Friedl, *Netherlands*

16:00-16:20 **EDB04.3 Plasticity of Glioblastoma**
Anna Golebiewska, *Luxembourg*

16:20-16:40 **EDB04.4 Sex Differences in Cancer Biology**
Joshua Rubin, *United States*



15:20-16:40

EDC04 | New EANO Guidelines

Chairs: Roberta Rudà, *Italy* & Martin van den Bent, *Netherlands*

15:20-15:40

EDC04.1 Glioma

Michael Weller, *Switzerland*

15:40-16:00

EDC04.2 Brain metastases

Emilie Le Rhun, *France*

16:00-16:20

EDC04.3 EANO updated Guidelines for the management and treatment of Primary CNS Lymphoma

Khè Hoang Xuan, *France*

16:20-16:40

EDC04.4 Rare glial and neuronal tumors

Roberta Rudà, *Italy*

15:20-16:40

EDN03 | The roles of nurses and AHPs in neuro-oncology

Chairs: Florian Boele, *United Kingdom* & Karin Piil, *Denmark*

15:20-15:40

EDN03.1 Role of the CNS in trial recruitment

Mairi Mackinnon, *United Kingdom*

15:40-16:00

EDN03.2 The role of AHPs in Neuro-oncology

Sarah Houghton, *United Kingdom*

16:00-16:20

EDN03.3 Presentation to neuro oncology clinical practice and research in Netherlands

Claudine Nogarede, *Netherlands*

EANO EDUCATIONAL DAY – ON-DEMAND

EDN04 | Symptom management and interventions

Intro: Florian Boele, *United Kingdom*

EDN04.21 Sleep disturbances and management

Katrine Løppenthin, *Denmark*

VIRTUAL CONFERENCE FORMAT

The EANO Meeting 2021 will take place virtually on an online platform. Sessions from the scientific programme will be accessible for registered participants via the online platform in various formats:

Live Sessions

Live sessions will be streamed live via the online platform at a specific time during the conference programme. The “live” element only refers to the live Q&A / discussion. The presentations will be pre-record by the speakers to avoid technical glitches at the conference day. During live sessions, participants will have the possibility to interact and ask questions to the presenters through the session chat. The session chairs will direct the questions to the speakers during the live Q&A / discussion after the presentation.

All live sessions will also be available as on-demand content within 48 hours after the session has taken place and until December 22, 2021 (EANO Meeting) or January 26, 2022 (EANO Educational Day). Once the live sessions have turned into on-demand content, participants cannot directly interact with the speakers anymore but can contact them via a messaging system within the online platform or via e-mail.

On-demand Sessions

On-demand sessions are available for registered participants from the first conference day until December 22, 2021. Interaction with presenters is possible via a messaging system within the online platform or via e-mail.

E-Poster

Accepted abstracts will either be integrated in the programme as oral presentations or as e-posters. All e-poster presenters will have the possibility to interact with the audience in one of the two dedicated slots “E-Poster Viewing with authors”. Communication and interaction will be possible through a virtual networking table, which is a small virtual meeting room within the virtual platform. Also, participants can ask questions to the e-poster presenters via a messaging system within the online platform so the presenter can reply instantly or via e-mail.



CORPORATE SYMPOSIA

Corporate Symposia.....	26
Corporate Symposium 1 Eisai.....	27
Brain tumour related epilepsy: what is the evidence for targeting the AMPA glutamate receptor? .	27
Corporate Symposium 2 AstraZeneca.....	28
Evolving Landscape in the Treatment of Plexiform Neurofibromas Associated with NF1	28

CORPORATE SYMPOSIUM 1

EISAI



Brain tumour related epilepsy: what is the evidence for targeting the AMPA glutamate receptor?

This promotional symposium has been organised and funded by Eisai Europe Ltd. This meeting is intended for HCPs. The content is aligned with EU and UK marketing authorisations and approved according to ABPI and EFPIA codes.

EMA-PER-21-00081 | August 2021

Date: Saturday, September 25, 2021

Time: 12:30 – 13:30 hrs

12:30 – 12:35 Welcome and Introduction

Chair: Gilles **Huberfeld**, *France*

12:35 – 12:50 Pathogenesis of brain tumour related epilepsy (BTRE): what is the role of the glutamatergic system?

Gilles **Huberfeld**, *France*

12:50 – 13:05 Targeting the AMPA glutamate receptor for BTRE

Antonietta **Coppola**, *Italy*

13:05 – 13:20 Quality of life in patients with BTRE: looking beyond seizure control

Katherine **Barnett Peters**, *United States*

13:20 – 13:30 Q&A / Discussion

Seizures are among the most common symptoms of brain tumours and can have a substantial impact on the daily lives of patients. The mechanism of epileptogenesis is not completely understood but is believed to be multifactorial, with evidence identifying glutamate as one of the key drivers for brain tumour related epilepsy (BTRE). Proposed mechanisms of seizure generation in patients with BTRE will be outlined; and data for this patient population from a prospective, multicentre observational study using an antiseizure medication (ASM), which targets the glutamate AMPA receptor, will be presented. Furthermore, the quality of life in BTRE patients will be discussed and how an individualised approach is required for choosing an ASM to help maintain good seizure control without increasing the overall burden to patients and their families.

CORPORATE SYMPOSIUM 2 ASTRAZENECA



Evolving Landscape in the Treatment of Plexiform Neurofibromas Associated with NF1

This promotional satellite symposium is intended for healthcare professionals and is organised and funded by AstraZeneca Veeva ID: Z4-36912

Date of Preparation: September 2021

Date: Saturday, September 25, 2021

Time: 12:30 – 13:30 hrs

12:30 – 12:40 Unmet clinical need and burden of disease in NF1

Chair: Amedeo **Azizi**, *Austria*

12:40 – 13:00 The treatment landscape of NF1-PNs

Darren **Hargrave**, *United Kingdom*

13:00 – 13:20 NF1-PN clinical cases

João **Passos**, *Portugal*

13:20 – 13:30 Q&A / Discussion

Plexiform neurofibromas (PNs) present in 30-50% of patients with neurofibromatosis type 1 (NF1). PNs typically manifest early, developing rapidly in early childhood and have the potential to cause significant pain, disability, and disfigurement, depending on their location and size.

Historically, the only treatment for PNs was surgery, but some are difficult to fully resect due to tissue infiltration and hypervascularisation. MEK inhibitors, such as selumetinib, have been investigated as a therapeutic option for the treatment of inoperable NF1-PNs.

This symposium will discuss the current treatment landscape for NF1-PNs, including data from the Phase II SPRINT clinical trial, evaluating selumetinib for the treatment of symptomatic, inoperable NF1-PN in children and adolescents, and case studies from early access programs, showing use of selumetinib in clinical practice.

Link to Koselugo▼ (selumetinib) EU prescribing information: <https://bit.ly/3DLfqQX>

EXPERIENCE +19.000 GBM patients treated to date globally

AVAILABILITY > 260 certified medical centres in Europe

OPTUNE[®]
Elevate Expectations

PUT GBM ON **PAUSE**



PUT LIFE ON **PLAY**



Optune + TMZ (Temozolomide) has been shown to **Extend Survival** in patients with newly diagnosed GBM^{1,2}

REIMBURSEMENT

in the following countries:

Austria, Germany, Israel,
Japan, Sweden,
Switzerland, USA



SURVIVAL WITH OPTUNE + TMZ

vs TMZ alone was significantly better
at the 2- and 5-year landmark analyses¹

YEAR 2 (P<0,001)

43% vs **31%**
Optune + TMZ TMZ alone

YEAR 5 (P=0,004)

13% vs **5%**
Optune + TMZ TMZ alone

Median overall survival was significantly extended with Optune + TMZ vs TMZ alone by nearly 5 months (P<0,001)¹
Optune + TMZ also significantly improved progression free survival vs TMZ alone
(median PFS: 6,7 months vs 4,0 months, P<0,001)¹

The most common side effect with Optune was mild to moderate skin irritation which was easily manageable, reversible, and did not result in treatment discontinuation.¹

References: 1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495-504.

SPONSORS

The European Association of Neuro-Oncology gratefully acknowledges the support of the following institutions, companies, and organisations:

PLATINUM SPONSOR

The Novocure logo features the word "novocure" in a blue, lowercase, sans-serif font. The letter "o" is stylized with a dark blue circular element. A registered trademark symbol (®) is located at the top right of the word.

SILVER SPONSOR

The AstraZeneca logo consists of the word "AstraZeneca" in a purple, sans-serif font, followed by a yellow stylized graphic element resembling a DNA helix or a stylized 'Z'.

SPONSORS



EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2022 VIENNA

Hofburg Vienna • Vienna, Austria

*Save
the date*



www.eano.eu

SEPTEMBER 15 - 18, 2022
17TH MEETING & EDUCATIONAL DAY